924 CYTOPLASMIC EXPRESSION OF PROTHYMOSIN-α PREDICTS BLADDER TUMOR RECURRENCE IN UROTHELIAL CARCINOMA OF URINARY BLADDER AND IS ASSOCIATED WITH TUMOR GRADE AND STAGE

2010 ◽  
Vol 9 (2) ◽  
pp. 290-291
Author(s):  
Y.S. Tsai ◽  
Y.C. Jou ◽  
T.S. Tzai ◽  
A.L. Shiau ◽  
C.L. Wu ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Tumor Recurrence ◽  
Bladder Tumor ◽  
Tumor Grade ◽  
Cytoplasmic Expression ◽  
Prothymosin Α

scholarly journals Incidence of various urothelial malignancy in patients undergoing transurethral resection of bladder tumour in tertiary care hospital

2020 ◽  
Vol 8 (1) ◽  
pp. 346
Author(s):  
Kamal Preet Kaur ◽  
Gurpreet Singh Bhangu ◽  
Darpan Bansal ◽  
Divya Julka
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Transurethral Resection ◽  
Bladder Tumor ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Care Hospital ◽  
High Grade ◽  
Urothelial Malignancy ◽  
Papillary Urothelial Carcinoma

Background: Urinary bladder lesions are a great health concern as it lies among the top ten most common cancers in the world. These range from benign, harmless lesions that do not recur to life threatening tumors. The present study was undertaken to study incidence of various urothelial cancer in patients undergoing transurethral resection of bladder tumor in tertiary care hospital, as the treatment, follow up and prognosis is highly variable with different subtypes of bladder cancer.Methods: A hospital based descriptive cross-sectional study was conducted on all patients undergoing transurethral resection of bladder tumor from December 2018 to May 2020 in the Department of General Surgery of Sri Guru Ramdas Institute of Medical Sciences and Research, Amritsar. Based on World Health Organization (WHO) classification incidence of various urothelial malignancy was calculated.Results: Out of 80 patients with growth urinary bladder, 4 patients (5% of total patient) were diagnosed as case of papilloma, 26 patients (32.5% of total patients) were diagnosed as low grade papillary urothelial carcinoma, 50 patients (62.5% of total patients) were of high grade papillary urothelial carcinoma. There were no case of PUNLMP in our study.Conclusions: It can be concluded that majority of the patient undergoing transurethral resection of bladder tumor are diagnosed with high grade papillary carcinoma. 

scholarly journals UROTHELIAL CARCINOMA OF URINARY BLADDER

2015 ◽  
Vol 22 (10) ◽  
pp. 1217-1221
Author(s):  
Muhammad Salman Zafar ◽  
Muhammad Asadullah ◽  
Usman Ahmad
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Bladder Tumor ◽  
The Body ◽  
Different Types ◽  
Immuno Histochemistry ◽  
Cox 2 ◽  
Urinary Bladder Tumor ◽  
Cox 2 Inhibitors ◽  
Normal Urothelium

In spite of the fact that inflammation has been regarded as a localized orgeneralized defensive component of the body to different types harmful stimuli, there hasbeen becoming confirmation of its strong part in initiation or progression of different ailmentsparticularly related with cancer. Objectives: Aim of this study was to recognize the pattern ofexpression and level of intensity of COX-2 in different grades of papillary urothelial carcinomaof urinary bladder along with significance of COX 2 in tumerogenesis of urothelial carcinoma ofurinary bladder. Setting: Department of Pathology, BMSI, JPMC. Period: 1.1.2009 to 31.12.2012.Methods: The marker of COX-2 was investigated by using Immuno- histochemistry. Results:COX 2 was not detected in normal urothelium, but its intensity was expressed as 68% in lowgrade, 72 % in high grade and 80 % in invasive urothelial carcinoma. Conclusion: Results ofthe present study indicate that COX-2 as a component of inflammation play an important rolein progression of urinary bladder tumor and encourage use of COX 2 inhibitors as potentialantitumor agent.

scholarly journals Expression of Caveolin-1 and Caveolin-2 in Urothelial Carcinoma of the Urinary Bladder Correlates With Tumor Grade and Squamous Differentiation

2003 ◽  
Vol 120 (1) ◽  
pp. 93-100 ◽  
Author(s):  
Andrew Fong ◽  
Ediberto Garcia ◽  
Lucas Gwynn ◽  
Michael P. Lisanti ◽  
Melissa J. Fazzari ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Tumor Grade ◽  
Squamous Differentiation ◽  
Caveolin 1

scholarly journals Predictive Factors of Bladder Tumor Recurrence after Nephro-Ureterectomy for Urothelial Carcinoma

2015 ◽  
Vol 06 (02) ◽  
pp. 122-128
Author(s):  
John David Rebibo ◽  
Emeric Lacarrière ◽  
Francois Xavier Nouhaud ◽  
Athmane Safsaf ◽  
Romain Caremel ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Predictive Factors ◽  
Tumor Recurrence ◽  
Bladder Tumor

scholarly journals Transdifferentiation of Small Cell Carcinoma of the Urinary Bladder from Urothelial Carcinoma after Transurethral Resection of a Bladder Tumor, Intravesical Bacillus Calmette-Guerin Instillation, and Chemotherapy: A Case Report

2016 ◽  
Vol 9 (3) ◽  
pp. 786-791 ◽  
Author(s):  
Kento Morozumi ◽  
Shunichi Namiki ◽  
Takashi Kudo ◽  
Masataka  Aizawa ◽  
Naomasa  Ioritani ◽  
...  
Keyword(s):  
Case Report ◽  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Transurethral Resection ◽  
Bladder Tumor ◽  
Small Cell ◽  
Pathological Examination ◽  
Bacillus Calmette Guerin

A 73-year-old male underwent transurethral resection of a bladder tumor in August 2010 and April 2011. Pathological examination revealed urothelial carcinoma. After the surgery, chemotherapy and intravesical Bacillus Calmette-Guerin instillation were performed. In September 2014, he once again underwent transurethral resection of the bladder tumor for recurrence, and was again diagnosed with urothelial carcinoma, pT2, by pathological examination. After neoadjuvant chemotherapy, radical cystectomy for tumor recurrence was performed. Pathological examination at this time revealed small cell carcinoma, pT3N0. It is rare for urothelial carcinoma to change to small cell carcinoma, and the mechanism and cause of this change are still unknown. In this case report, we discuss what causes small cell carcinoma of the urinary bladder and review the literature regarding its origin.

scholarly journals Increased COX-2 Immunostaining in Urothelial Carcinoma of the Urinary Bladder Is Associated with Invasiveness and Poor Prognosis

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Basim Al-Maghrabi ◽  
Wafaey Gomaa ◽  
Mohammed Abdelwahed ◽  
Jaudah Al-Maghrabi
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Distant Metastasis ◽  
Immunohistochemical Staining ◽  
Lymphovascular Invasion ◽  
Tumor Grade ◽  
Tissue Microarrays ◽  
Clinicopathological Parameters ◽  
Cox 2 ◽  
Muscle Invasion

Background. Urothelial carcinoma of the urinary bladder (UCB) is the commonest bladder tumor. Cyclooxygenase-2 (COX-2) mediates angiogenesis, cell survival/proliferation, and apoptosis. This study investigates the relation of COX-2 immunostaining in UCB to clinicopathological parameters in Saudi Arabia. Methods. The study population includes 123 UCB and 25 urothelial mucosae adjacent to UCB. UCB samples were collected before any local or systemic therapy. Tissue microarrays were designed and constructed, and TMA blocks were sliced for further immunohistochemical staining. Immunohistochemical staining was done using a mouse anti-human COX-2 monoclonal antibody. A cutoff point of 10% was chosen as the threshold to determine low and high COX-2 immunostaining. Results. COX-2 immunostaining is higher in UCB than in the adjacent urothelium (p=0.033). High COX-2 immunostaining is associated with high-grade UCB (p=0.013), distant metastasis (p=0.031), lymphovascular invasion (p=0.008), positive muscle invasion (p=0.017), pT2 and above (p=0.003), and high anatomical stages (stage II and above). High COX-2 immunostaining is an independent predictor of higher tumor grade (p<0.001), muscle invasion (p=0.015), advanced pathological T (p=0.014), lymphovascular invasion (p=0.011), and distant metastasis (p=0.039). High COX-2 immunostaining is associated with lower overall survival rate (p=0.019). Conclusion. COX-2 immunostaining is associated with the invasiveness of UCB which may be used as an independent prognostic marker. COX-2 may be a significant molecule in the initiation and progression of UCB. Molecular and clinical investigations are required to explore the molecular downstream of COX-2 in UCB and effectiveness of COX-2 inhibitors as adjuvant therapy along with traditional chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document